0001557142-20-000088.txt : 20201130 0001557142-20-000088.hdr.sgml : 20201130 20201130085121 ACCESSION NUMBER: 0001557142-20-000088 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201130 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201130 DATE AS OF CHANGE: 20201130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kadmon Holdings, Inc. CENTRAL INDEX KEY: 0001557142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273576929 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37841 FILM NUMBER: 201356429 BUSINESS ADDRESS: STREET 1: 450 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-308-6000 MAIL ADDRESS: STREET 1: 450 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Kadmon Holdings, LLC DATE OF NAME CHANGE: 20120829 8-K 1 kdmn-20201130x8k.htm 8-K kdmn-20201130x8k
false000155714200015571422020-11-302020-11-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

   

FORM 8-K

  

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 30, 2020

   

Kadmon Holdings, Inc.

(Exact name of registrant as specified in its charter)

  

 

 

 

 

 

 

Delaware

 

001-37841

 

27-3576929

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

450 East 29th Street

New York, NY

 

10016

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code (833900-5366

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

KDMN

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x


Item 8.01

Other Events

On November 30, 2020, the Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company’s New Drug Application (NDA) submission for belumosudil (KD025), the Company's Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of patients with chronic graft-versus-host disease (cGVHD).

The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits   


Exhibit No.

Description

99.1

Press release, dated November 30, 2020, issued by Kadmon Holdings, Inc.

104

Cover Page Interactive Data (embedded within Inline XBRL document)



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

Kadmon Holdings, Inc.

 

 

 

Date: November 30, 2020

 

 

 

/s/ Harlan W. Waksal

 

 

 

 

Harlan W. Waksal

 

 

 

 

President and Chief Executive Officer

EX-99.1 2 kdmn-20201130xex99_1.htm EX-99.1 99.1 NDA Acceptance

 

Exhibit 99.1

C:\Users\ellen tremaine\Desktop\Kadmon logo - blue - 5 26 15.jpg



Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease



– FDA Grants Priority Review and Sets PDUFA Action Date of May 30, 2021 –



– Application Being Evaluated Under FDA’s Real-Time Oncology Review (RTOR) and Project Orbis Pilot Programs –



NEW YORK, November 30, 2020  – Kadmon Holdings, Inc. (NASDAQ: KDMN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company’s New Drug Application (NDA) for belumosudil (KD025), the Company's Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of patients with chronic graft-versus-host disease (cGVHD). The FDA also granted Priority Review and set a Prescription Drug User Fee Act (PDUFA) date of May 30, 2021 for the completion of its review of the NDA.

“The FDA’s acceptance of our NDA for belumosudil represents an important milestone for Kadmon and further highlights the efforts of the Agency to bring meaningful new therapies to cGVHD patients as quickly as possible,” said Harlan W. Waksal, M.D., President and CEO of Kadmon. “We look forward to the opportunity to bring belumosudil to market as we continue preparations for a launch, if approved.”

Kadmon submitted the NDA for belumosudil on September 30, 2020 under the FDA’s Real-Time Oncology Review (RTOR) pilot program. This pilot program aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while maintaining and improving review quality.

The review of the belumosudil NDA is also being conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among participating international partners.

The FDA had previously granted Breakthrough Therapy Designation (BTD) to belumosudil for the treatment of patients with cGVHD after failure of two or more lines of systemic therapy. The FDA had also granted Orphan Drug Designation to belumosudil for the treatment of cGVHD. 

The NDA submission is supported by positive data from ROCKstar (KD025-213), the Company's pivotal clinical trial evaluating belumosudil in patients with cGVHD who have received two or more prior lines of systemic therapy. On November 25, 2020, the Company submitted 12-month follow-up data from the ROCKstar study to the FDA.






 

 

About ROCKstar

ROCKstar (KD025-213) is an ongoing open-label trial of belumosudil in patients with cGVHD who have received at least two prior lines of systemic therapy. Patients were randomized to receive belumosudil 200 mg once daily or 200 mg twice daily, enrolling 66 patients per arm. The primary endpoint of the study is Overall Response Rate (ORR). The ORR endpoint was met at the interim analysis, conducted two months after completion of enrollment. At the study's primary analysis, conducted six months after completion of enrollment, belumosudil achieved ORRs of 73% and 74% in the respective arms. Belumosudil has been well tolerated and adverse events have been consistent with those expected in the patient population.



About Belumosudil

Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and pro-fibrotic processes. Kadmon has submitted an NDA to the U.S. FDA for belumosudil for the treatment of patients with cGVHD and the NDA is being reviewed under the FDA's RTOR pilot program. The FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD after failure of two or more lines of systemic therapy. The FDA has also granted Orphan Drug Designation to belumosudil for the treatment of cGVHD.



About cGVHD

cGVHD is a common and often fatal complication following hematopoietic stem cell transplantation. In cGVHD, transplanted immune cells (graft) attack the patient's cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are currently living with cGVHD.

About Kadmon

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.


 

 

Forward Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) the impact of the COVID-19 pandemic on our business, workforce, patients, collaborators and suppliers, including delays in anticipated timelines and milestones of our clinical trials and on various government agencies who we interact with and/or are governed by; (iv) our reliance on the success of our product candidates; (v) the timing or likelihood of regulatory filings and approvals, especially in light of the COVID-19 pandemic; (vi) our ability to expand our sales and marketing capabilities; (vii) our ability to expand our sales and marketing capabilities; (viii) the commercialization, pricing and reimbursement of our product candidates, if approved; (ix) the implementation of our business model, strategic plans for our business, product candidates and technology; (x) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (xi) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xii) costs associated with defending intellectual property infringement, product liability and other claims; (xiii) regulatory developments in the United States, Europe, and other jurisdictions; (xiv) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xvi) our ability to maintain and establish collaborations; (xvii) the rate and degree of market acceptance of our product candidates, if approved; (xviii) developments relating to our competitors and our industry, including competing therapies; (xix) our ability to effectively manage our anticipated growth; (xx) our ability to attract and retain qualified employees and key personnel; (xxi) our expected use of cash and cash equivalents and other sources of liquidity; (xxii) the potential benefits of any of our product candidates being granted orphan drug designation; (xxiii) the future trading price of the shares of our common stock and impact of securities analysts’ reports on these prices; (xxiv) our ability to apply unused federal and state net operating loss carryforwards against future taxable income and/or (xxv) other risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including Kadmon’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and subsequent filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.  

Contact Information

Ellen Cavaleri, Investor Relations

646.490.2989

ellen.cavaleri@kadmon.com


GRAPHIC 3 kdmn-20201130xex99_1g001.jpg GRAPHIC begin 644 kdmn-20201130xex99_1g001.jpg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kdmn-20201130.xsd EX-101.SCH 00090 - Document - Document and Entity Informationlink:presentationLinklink:calculationLinklink:definitionLink EX-101.LAB 5 kdmn-20201130_lab.xml EX-101.LAB EX-101.PRE 6 kdmn-20201130_pre.xml EX-101.PRE XML 7 kdmn-20201130x8k_htm.xml IDEA: XBRL DOCUMENT 0001557142 2020-11-30 2020-11-30 false 0001557142 8-K 2020-11-30 Kadmon Holdings, Inc. DE 001-37841 27-3576929 450 East 29th Street New York NY 10016 833 900-5366 false false false false Common stock, par value $0.001 per share KDMN NASDAQ true true XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Nov. 30, 2020
Document And Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 30, 2020
Entity Registrant Name Kadmon Holdings, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37841
Entity Tax Identification Number 27-3576929
Entity Address, Address Line One 450 East 29th Street
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 833
Local Phone Number 900-5366
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol KDMN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Amendment Flag false
Entity Central Index Key 0001557142
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.kadmon.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports kdmn-20201130x8k.htm kdmn-20201130.xsd kdmn-20201130_lab.xml kdmn-20201130_pre.xml kdmn-20201130xex99_1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kdmn-20201130x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "kdmn-20201130x8k.htm" ] }, "labelLink": { "local": [ "kdmn-20201130_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "kdmn-20201130_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "kdmn-20201130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kdmn", "nsuri": "http://www.kadmon.com/20201130", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "kdmn-20201130x8k.htm", "contextRef": "Duration_11_30_2020_To_11_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "kdmn-20201130x8k.htm", "contextRef": "Duration_11_30_2020_To_11_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kadmon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "kdmn_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.kadmon.com/20201130", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001557142-20-000088-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001557142-20-000088-xbrl.zip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

=O, M\ZFB06@'Q?]+.U[JE]+B"+I$=F]*'VKC_=F1K';^>9%TO'^-)#Z/#XRA(WCG MQ\]WNVW6Q+R;;23_D:[8SXIBYWC9L@.1H>WA>65;YWPONH14T2JYVO]H""+L!5>1UX MI=/M$))<0+OR!=I@C0,RM\Y;OVCEZLX)!WF?9YL;?#5;>/H74$L#!!0 ( M &I&?E&(TPDJ&P8 .D\ 5 :V1M;BTR,#(P,3$S,%]L86(N>&ULS9OO M;^(V&,??3]K_\(Q[LTD7(&6;KJCMB:.]"8U>JX-IIYVF*B0&K LV3[^D9"[>+]9Q/"(6((IN6SXS78#$ EIA,GLLK%* MI]Z[QONK'W^X^,GSOGSX/(2(AJL%(BF$# 4IBF"RA3YBJ3AUC9,PILF*(;@- M2#!#4OA[LW/>;#=]\+R\HP]!P@,I =GC6=/?M?3S3BGI@N^W.NW66?NL#>^Z MOYYW?_.A=[M3WG*+4WQ8&F/R;<*O!SQ/DEPVYFFZ[+9:Z_6ZN9FPN$G9C >V M.RTE;&3*[B;!!?6ZH[1^Z\OM)$E9$*:J(VD_Z^EY<5<7+>YE9U.$ M]UC1:\!"U3T_/)!ZKFB%E-=ZF7JR1Q4^973Q$G/*!GU!T$,\B656>2J%U IY M,930%9-$/KNH:E#+2W[O39<6Q3#@D6+R0,3[:]2X4J$0D(A/+2(8\#ZZF>?T MN@D5ZO/:B?!8R(+A231\5?'_EE-ZSBC)\Y&Y3(-D(A-:)=XL")9R9FNA.$W4 M&3F>O+:?C_(W^>F'$2^AG'7'P21&I1M@$3D8*]5VQ< P*XX["DS05/C0"=F) MX*N4G0((?-)' WZ8'$IL+SP%(#3;1BAVJA, H^BE$@XA!:G];D(2A4B"PN:, M/K8BA#,Z^$$9"GYJ-_&->;^E5+1F!P#8+(JRE]OJ+[;10<4*(31'6==2OE%' MPR,Y/#I[]XAARM?=Z)H/A8H$BCK'-!I-E[$LB-SRJ5NIP" 3\]U,!$+NCMG7 M='TTCK--WV@ 8@>:D;M(X[1I]5B@I@UX2<2IQ#I5HO$[-M=XE%R865!Z" 3UESR M<; 91.(ESQ1G+S8/U-^F=PK#@22*9%C$+C&ILF1EA@=!,L3%=EU]> M5RE/@13=N)&3O>P$*"F9.P+,F!P=!F>WB55Q;NBYITD:Q/_@9>4CDE%\"N08[1NY*2A/@!K=SV%F MLAC@0?4^\HA)KL=08&&DT.R("I-%Q<'3-C>5UQSHM98+B=#46UKQD49\/Z?$ M_C2K21R5V&95E;G<[J;41A=ZN:4,I*[N9Y&_&4Y31/ITL5B1_'FH_ NJ7>>H M^)6F%0%&D1L,[%9T%G(M%,6U\3"B,0YQBLGLEF])& Y,^1A$CDBPVU48Z HW M#%A\&'X^WPE!*6NK_CU#@CO$[[G\?55\-,?NIE/C4E A=D3#8?N*"KO2#1T' M_.B4\ O?!(!60C(&%>\#))DA=B+J-%#3H,=:RH6@C3]27!D=O4,FK) -U"- M4+CBB^#6/YN,<:I]W&>4N%I^+%9WBT^IW='28W*A0R#;@$[!/_MY\@NHJ-KJ M/F:!^!A_M%U,J"F-8KNCBAM-JG(7&MW46K=@*'2F@4Q4^[B^V81S;@=9/BHQ MRAR/;Y/E\AA_JG$[SC4GADUF+@6E=?&%QLT"L1D'\0]&U^FE0AD,5 'E0W-1L^?Y$$B^?B[/LX>XZZU"TO M5NLE6#2=4U+,;NR8;& ?D'_"6!LC/;Y]C<06]F,(_]_CD>>I/K\N"^(!?X+:_(GLZUI9YW2&LI@N3D\ED MJ*D+I00 HM 5 :V1M;BTR,#(P,3$S,%]P&ULW9K1;N(X%(;O M5]IW\&:N0Q)"2T%M1PSMK-#"M&J[FM'>C$QBP&IB(]L4>/L]#B1M((&@T6Y3 M7S6-?]OG/Y]QDI-EP:4?8\AOD0^&3RRIHI->\ZSG*Y;*S&(FIP,86.KN^D0FNC[*XDS:F7?JKU MG!^CX6,P(S&V*9,*L^"UEQZFJ)_7Z72-YI -/SLT$F5Q9SV', M;)U'S_-=W?_3S99W^K?'PENFJ%H/V(2+.(G>0GK\OQ\&.1O/.(PY:P0\=G2S M4VFDZTMG&^LF\+D@$K1)XQ#BW$:K-;\^62X=9 5K."1A=I8J/8?KNAT7V2@= MZ.TA9B':C(IR'G3D$'O$@]P,D8;-Q;&,ZS,_#\7=&TLE<*#2@2(\)M%FI&K] M(,D0RTEAZE1+R'6R\B0)&E/^XH2$)C\Z?9!XL%UON^X^P:DLF"<8=R?8W>:? MYWZ[U?2;S4[':_N^?]8YVPGS[4KHB7S(6 3I^'"XMSCR/Y>MPIEC >/9P8Q& M&?2)X/$IF4RCX-4<(2Y"(F";M=!"0HQ\KD?#D87 W80(0<+A)C^ET2>A*]BO M2:+42=K)S/_']9X(RB$[X0ULV@< YW1FD3YJ+47>_-C(-XEY(%.J\\'4-QP7 M$2^2F0&\JK.4MV\"[P'<"8HY%\F\CS ]Z?,%4V+=YV$Y_H.]3%H-)QM-%T=K M=W&\'^*O-"+?%O&8B%*>KQ*3X!UVE9(ZJP^I)[P:A# O//9L'AJ.8"O1F\3P M!(LIT//Z .V%(4PLMW_@Z89XI3 +M":!K&@OA=BN'<0^'-Z))[YDQQ"^*@T$ M>-A=N!?\A6ZJ.0<9[LCS7ELMM]W\Z" K.$QI=FI'\YY+A:-_ MZ/S@;6J1V$"21_UE10FW#B#U#M(3!)>@>]ML!JQCCC(\>T6C]\"C"];1_8RS M\H>&78D9F*JXRE#M%7O> ]5W094BK,_C>,&V]\>R@%>AS@QHE:UEY/;*-N]! M[I%'-*"*LND(KL*"ZNK1'K9]D1G,JOG*@-6BE'(OB%YC!.Z4DO*_?I$D[B:3 MPOVQ7&P&P-/\92!K46G9B7T@Y8*(DW#N=3$2:B67&=I:U%P>2;" R\'::XZ? M]*O=HBUU1V(&NBJN,E2UJ*P\":R_/WE=.G+M9L!Z:BEC% MBB?IFKI= M!3/,IJ3D=6"1S Q>59UEV&I4);F-B9C"8OM3\*6:P;8^QVQ=6B8I5)L!\42# MV:O\6A1*ML&O8.=@DNII-]\BE(/_47*-]D=73XQ;?^BU?Z K"M;RYC_MQ_-Y,\, M(52=4[KY;O;Z7U!+ P04 " !J1GY10O*QQBP6 !.3P$ % &MD;6XM M,C R,#$Q,S!X.&LN:'1M[5WK<^,VDO^^5?L_X+2WB5UE2'P__-J:V)[$-1F/ MRW8NV?N2 @G0XIHB%9"RK?OKKP%*LF1+LC36@Y*05(U%$@0;0/Y&X_A? MSZT$/3*>QUEZ4M/K6@VQ-,QHG-Z?U#I%A+W:OT[__K?C_\+X,DWBE*$_?KKY M%=$L[+186J"0,U(PBH(N.F.\$+?.XSQ,LKS#&?I*4G+/9$&H6OR/<:^VL]Z+ M67J(=+UA:@U#,S2DFX>V=JC9Z/IK6;19 (% 9)J?U)I%T3YL-)Z>GNI/9CWC M]PW=]_W&LRA3*PL=QL\CY9X#GLB2AJ:;C5@V0;2@7QRN'R:]H)D-\3@@.>L7 M?WY3?H00\?2%D&)\Q2]$- I.TCS*>(L4T/^"1AMK!C:CZ,:VJ@W_OCZZVW89"V"XS0O2!H.6DO9RUN2_/ZGX8$<+JSI M0Q]YH*UTY"L/A+:RM!YF+5E:UTUM0!!4%T_I^ $IP ,('3<9H?(7_"[B(F&G MXF.X7^NS]W#<*._W"K5809"H';._.O'C2>TL2P5WXKMN&]H7EE3DCW,,U2(/8X M?CX4=3!>_HPI9:G\"<^O0&1X'**4M,2++#[\!*)!A7A\3LA]#<7TI!86^*4H MCHCMN0ZPA&6&\(_&;!PXS,<&U1UH. D"V^JUYKFX8=%)[;S#)1/\J>M_FMJ? MHH?^O,N&KFJH9)23&C#789!E"2-I1!)@\E/YY[@Q0NYDZB]2Z/+N&9#/27*9 M4O;\A77'M<*UJ$F=@.+(- )LA:Z# XLP;%NN3W3F!:;KS=N*4PUXU[9=W3+> M$-P8[7K.(L8!U5A^>BPD]#"7[ X?0E)B#PO@B9-:'K?:B>!]>:_)!1TC7%9_ MSBD,<6.TCO)SP]^0EWG6X?)*+R7![_'SM$%A E0!XW64F!KGG_/&H1?A^G0]_KW2CI'ESVB!Y<2XHE M<7F;I'VJGIIQP3#<"=EAFS/\Q$G["&0QR?@A^H> M6+^?Y+WRN^*;O2XJ/X^.&X( &+!V;] 6U%NZM_#NLNJBO8)%,$GB>VA,"%+# M^/?WXGW=I[N+V^&.KVR7:YO7M[^>UJ"6-@;-<8&!\<@]])WH2+(DL/ MT'G]K(X,S;;\X7[?_(EAMC$WZJ+8-HW[])GEAW_HCG94_ML?[Y60KBV(] V: M&>5P;3!2?_YV\W6@B4Q:X9SWS!SEHG',PD9WJ1M2#18V.L,6I2;VP\C$U-:B M2#-T,W""N18>D!2HR=,M",<&4/*^;*.-(M_?HOAJ%98]"%J&BR<0 M='AP2=)[ACZ%!8+'NF]:&S$.NEG?< @29D?1Y3>LG?$"[?6O&>$) M#$V!V*-P2W'YF-']PYF5P6MIP[PH+9OCM$(KTFGDT0#;-"+8LBT3!PQ^^;9O MNV[@,\\V/V2TI_#A%KS>I*3;A0:Q=%-&Y2I[9*V <61J!T@T3.F0VX:06ZL_ M+E>+-!9OZY^B14YWZ=VP^S@7/N7B"IZ,A3C3,6S#<;#E!RY^QBP.C&D0]D4ZM=$O4 3NY0?H,@WKTV!L05"B;1>4S"*5TX9A M[^*9@%(E6%=,ZWS LHCD*&^S4/@Z*8I3%!>+G9YBWDXN M0TPZ-"AB%&% "A(D["TGE2PXRH_0R(2T8EHT M1:.U?PJN*'C_NWTFU.J:'J?R&1TK82_=]$*@^."X^_++XQX JX[NWU[3J98/'R.ZKH3E"BP%XW1:??#5. MLMQJ//Y5D(*";CH;E34-Q&;)7+16)GI%R"+C1#:?#U[!B:$884<900&"X@,% M" MEA$;!)VBB]E1-]"V/?&AE5RF%\FW,Q]@!7T;XZ'=2NTKE<;4COU+(5P-? MG8%?+<:KD:_.R"N1W]&!5R*_AI&?J #J;H440+@]B_:W1.OA0AQ$T[V'EVF8 M\796NOMN"U*PLZR3%KQ[EM&QSD2-^<36;(8MC\(_CF5@S]1L3(AMF(P:AJ;9 M'XF7$#MHQ::U@K5Y]BC(75W Q$?=7.',::FDB+X#K6;J"+05;"K8J!EMWY/FREPT@E'@S!<-L 50FP8QX M'JAFOHM]"DH:<1GS2&A:H5W5#4X?Q3##Q:;M.K[AOPMB$QW+5(W9>9$63%YBFXH)U^MQ-IZ)@,33%3T.*S3;O?J*4LSSO_?D5:-+'YJ[R M3=.R=!L[.F/8,@(+>\34L!88-C.T*/*]N;WN&V+:M6P-79"\0"^VW8V@^SCO MM$^+)M#<$3*X092CVX(S5JQEF_1R-;^99/$,?G[C=]E3.DX2/=,/PY":6!.I MO2W3L7! 70][ONM$KL%,8FZK)(KZT;\S_C"),S:B%0?OYHX9X0;I'?C&KWGV M&,ML^V]90M==C]B^CPTMM+'E&@'V'5O'MF<'IF&8MDDJFE_AXRSQ;Q4TH((& M-LEP-,H)VQLWT(.OZRPO2/*_<7M2/*=)J!^%FHDC/X+YS*$VS&?$@%]VX ;4 M\CR';2EXZ9JF.]\?+Z!;.[=P4K;15[;1GI2)I#9M#OI!W"8)8L\L[!3QH\AU M$\4ARY4O1?E2*CPE*E_*RO ")F(D9N()QOR&3!*TX(S'B\]%MNZ,QQ^=^%]2 MYOWP#\_0W:,<%2QA[2:(#TJE^_M A"0E'?$.(IP1()LRM%%FG+WWUKG"T/$) MVC9)-0P#JD6FH6/-I ZV(IMB3^B'C#F&0\.01N&VQL1[IKG11H[]T?EF$@?\ MFL$T<"W8?G)4L:^'5*,:,(#FA=@BFHNAN3;6+#ORB&E34YBLMY(+?$W#MNE, M72,HD%Z6::GQ:16A!IN('Q7EY.+K=APB4I%S4P!4:H3(D.6JHP M?J)$^&'*+-S;EIUS&1E;/WAZWP(L<,<%,N"I11DJLA K%J=I" IRSIY MTD4YS)MYU)5O]E[( D"6,@BH=V3!4/;<#M0#\IIV^\^B+(&/B_?$[NE81,[F MAQ,DM2HI2KG0VMK0ZPYTB$H:-C=NS1C%M'DL87ENW;054WPPDUSU[&@? MD/7?X0OB*_EJ7(J3EH:_\[B >4KLP.BDO3#4?-SZ$/J$1K;C8,/5?6Q%GHX# MYIB8.M30-3M@4>0L\-3S#^H'DWOWH_9=!Q;DRL@ M9EBP4'OH4+";#FAAEF'WU+M7QU2)TZGV=!>=?;Y!AJG5H>#$T' %C(L'QEM8 MT88P%.G]5]#X0>U/QMI.S4 #8"286;J#+9-XV''EI=YWF'\'PV(X[J6/7=PIL+,W<',-;JP-@ Q38:MO7 V MQ.R5767]+*47;V+6"Z]6(!*!R#CC(XP=>\L>:1+-:#G M$ 1&GN3_>^W'&,*@,HQA%1Y!Z0$\QCRV7" M*P8:O5F)J62FU<;<^_8KK('=Q44BCR]G)&RB,"%Y/OM^GEUAO!5,8+O'>)S( M?2BWW5:0)7OS;"?<%;9;Q:2YWC'^J816&$"D7#G91FJ)N*MG(@G M1D"4IHBN;@1R3AR;)D>G!C4L#\,*GF!+TR,<>"[%;J 1REP]<,.EI!584S!X MUFIE@K(L?#A ;<+1(TDZ#/VW)FP>J,TXRIL?.AAJ5^1ED_6'2?+2F[_+Z7ML M B$6V8P9+HX<0\<67&'?H &F%K7"@%(2!ELD+%_.OUXI0=AJC>:]F:/O9Q$: MQCB!H(;K&9IMB1\1MKR0XL"G(!K4]AR7N$0/PP\?,B@TFCG.%UR7#I93\M?W M[T5>#]7HYR0+2()N6<+" GTE_&$HGV!%4AXX\S%VQ?U#ERD5KDZ&@BX*Y=XT M*/@ JCJ3I]J\VC@6YPB:P8"-[L7*\IX#P#6%Q[0M-I.1'%$60?]1%*>OKLK@ M9,WN.YA>12;#7=TW3;0G-J"[1S) N5\8/@IBWX8EP[[8;5HZ88T &V/J&O'$ MEI5:@TJ%0_;EO:%JZPA=3&C3;$G_^F__+%\^*]\=AU!1H,/$[(?88+8'"!6% MV+<<(G;%!S3T+0/TW$5$9A2\LZ3 C(_GM)E7%G[XJY,51P-BRLO:Z?, P MEWVE%_"7T10I%QE.QD)&_&:;:1,@0"(Y0$":26=S)V>R%'!W;S,KE,QCZ8"& MY4Z<4<'-\EM)5WS\*89/"T%,H=GPA+/'.(?W %A(&HK@7Q*&XNAA43@O2$H) MIWFYC95.\G2;>V3@Z1Y&#,"!&>7]^6Y ][4D>VR.O,B/PE S<,AT"UO$L;!G MFA9F@:6%NJ6YQ)\[$8H2]LD+ *$*_/UO"/X[EEJ!"%J0]G8A]1D _1E\B8 < MBQ"%4G%H\GZ)-KEG/W%&'@9(T6N1#IV A% A&%U1"@>B&&C=T.U'Z.4.)E$A MHAM(\D2Z^5$--49(:#)"QY'PANP%@59U=G!N2C#0UF5N4+OVUQ>18=2]I:[" MC:J(MZ&B,J8D1G3<)6\(VVH^F'Q4D<(+E=!!X87B@QGQ0O>J>4CW\L5^QO&> MTZJYNAT>L[#)U!/Q"M8JLUIZ,&M4/Y/R\@%@C3M$*L /WZ1=^^*1I<7;.+SE MN1;>=KJAC8-=8UXYE"P1I^+<1P%TME8"W7)LBQ_'[&_B4,I')K+&(E,[0,*H M=2 -<3VK.8K%#D>*"&K+%/F<)8SD#)$TS3II"!65TEPT23%'8N7UM%:TZS=Q M"NKG+(,FI12=\\X]^D1;<2JMI-(>N??Y_-.^M):2,&1M82X51M!K'F?"ZXEN MV&,,I YUTB#_M&A"666[G?1/_=R[$O7EG:!W"+:L+6!)IY7E'1HG:._+N6;8 M^R/]_@-I9SG4>-/,,,GS+!2)"<7&R#AA%(L_Z"%.Q4@8:._FV]D78Q_%:3,. MXB+C!_(3HK:",U+(?73B; .@1\A9:<4-FSQ+XQ#=^//__'*^7U^"M6=6^?.V7/[N1+;'3I(@&9C0LX&/2IIP\A4%"9MEKDGI M*3OK<"X&]48F<17!?(,,E41XW20?(-^OZY++9;K*,.-06'(10"Z+4^$PX"R" MWVG(ZEMIJ%**Y.;9DY4>6 D]<(F#JY:%51_\M2T*?;4HG O=YUZ?; I+?!X$ M%,BC.UM2;Q6Z3$^YR>MK72V.'XVYM=4*:Z9[='_0UZ@4SK>G7RE%\<-3BU[W MJP$E2E%<2,I)7?ON!$%G\"3@\0Z-WD1-T/25N$X=<'N^\;9G#7M>ZE+@.."H M<2JL99IS-+NQ<.WJB!Q8RL*LM! >EKFFQ"A!H_K6EJOLK4I2-?;]"#I]-_^. MB>-:)?=6AU/.61[RN"T>;$[*QG4@WO9QS'1<%(9:A1W+L8+T.(&@)A7SY[4PRU2 N1YV'!P@*HW]8_Q[/9]>T$5? M"!5;GG\!0!/QW0?H,@U?IC$RT>=3V>&NM,6S>D*MT'WYZ*YKE@+WI8+[S(P0 M)"1\6!,;G $.9T/VQ'1"Q6XN$4<0I] < M,:[HCY]N?D4T"SO"6+O91Z.KK2-JZX@*!5>AX"H47&T=J1Q>;/46HZUA [75 M3.%%-?!BRWV(6\,(U0DKVFR+FQ(C!;A*05,*VMKA=JOY8/W1EG-WV]"8HO)L MI V8NBK5@ZOHKFE1P0L,(%K25*J27E6'$7=84!<)=2N._+^]_/GJT]UO-Q>; MT]^Z63DG:2+0M(1*2'E1E5> M;E"%SP0,Y<".\"!+D=A3$+ F22(1A"(JDF$LO0)B>VHGA7=D=:13-#,.+:>K MV8B\[JERYU6":.B26ZW?-JHA.9Q3@IX[TVRKTW03975 M0BU5E-5"#;ZR6BANF&RU& I*?T5?GB6Q2$:6TNQ)GJ.EU\7H+8KB]3/C!A_[ M,IT3&WD#_4)X L3^7D>_DX><)&^VTRE77.681^'6AFBT6XL]]L:T^"NG!>FJI%*@:S>4EA!QH;HD,H44@5VJ(8:J;!@IS5) M!055X 85R[6:)#F#DY7S$N:'1M[5S[;]LXMOYY+G#_!VX& MLYL MF,G;:=Y3''3))T6G39S^YCB @,,:(FVV4BDAI3L>/_Z^YU#2I83ITT7 MJ7>2;HLVCD21AX?G\9V'?/BW;O?YNU>_B-0F5:Y,*1*G9*E2,=/E1!PK5]+% M$^V3S/K**?%*&CE6//11;W>OU^\-NMTG__U?AYCI.#YKS;X8#+9W^]L[_9V^ M>+S_L+\_>"".7H61DS+/\/.[PXF2*7WX[K#49:;XXW=[>[V!>'UR)(Z21!6E M-(GB(=O-F,/M^L'#H4WG3PY3/16^G&?JIXUCR) M5S:6'ICIM)SL#_K]'S8P(Z]4+$^VW\=#I;HHNS+38[//4QV,K"F[(YGK;+Y_ MC!M#I\,UK_^IL'T\5$_XW=_-T!<'N-Y3)^=C9RJ3=Q&;6 M[8OOG_&?3U/R3N?*B]=J)M[87)I5%(&>0RF,S+'@V2^G?_SRXO7+P8]@RK9\ M)7HJ7>;:E]D*#&MHL/0@; M_[[/?UI;H9W@%$\O)GJH2T$"<[A-MY\L&'P=6ZU+E>L.;5G:?']0E,)8H\3W M)WOT5WSV5 <+'GYV*Y\]$IJ-I%'G8^%=\M/&>9J;+JG,8+#;OU 7>WM_#,;] M_J#WL1AO+ NL&/0>/7X\&.QI-#???10FPTAL_*GC>/]W]][ MY?SO*LN4$:53N02!OY\H?U[:XO>7,LVM$9D=6]$5PZQ2^/%0[#P2@X>\ZI,O MY"PF_1?8VK\96S>>_/W[BV>G4(*;4/4(9/3COUW\-3L3/3H[*[F^0C,IWGUO/)EY)KVYXW/>&L5\B4'=L MW_S!*X5W(N=OL= 8,U$/5TWR(?OW$!.BH*#) L&T^5-F-Q.I59Q4CP/;;B M2,3"Z+T##]F269?6$V>&//RX$;?--^_.WFRQU/WJ[$>5E.+,#37$3V>VI&MC M)W/_I;+6YN#'RI=Z- ^7XB_[FKC:U:FB^8O)W35,C^[J9E^??A#_=_;F94?$ M[7[-M>Q4Y4-(Y==?:K?_]==@^WL[Z[2G%2%FN:1JMS=_F/[6IXTXZ3E8!4/D M.^*%27IB\_6M+W3T]N3H?V]]UGWQ\N35ZRU1VA3.]=:GEQ$^IJ*P!54W7Y[T=QYN==H3_0/>8F*[TGN;:/8GB=69HI 8 M3YQK \ J=N WSHY?[FR!)1P06M?AV6FBDC(2G*P 8"F6H' 2H?"8H? T0.$) M0>$T0&&QF?S\V_.3K9YXAYD()LG,6QIOB)158,FK4DC<43YQN@AHB;9/,9AX MIA1!*+'):&I+I*MP5$UX @YDBF? $ VB75@&O]%]\+#WI:YA-=KX"_J*JS#C M^"">P4*VY%+T8RO71$!ML7*JP&GPJ4LC=%Y8AV=*@<65+RE(I2>BV: C'%4. M_'5B C9EQ"K/_%:CT:VK(TCQ]7D>C95)YE!\ :8"0MWZ8KF2!A./JDR8H*XX M4HUGL"3+^4(]H.I_5CHYS^;TL;#>ZV&F.H'U)P?"2YV*Y])EX.B'GO@@S[W, M.N)5[Z378>'7A%^9F\>G9[3#P-^>J _S@Q*9M>?$^YET*=% 3+ %'4]E2*L: M3K1/$QD9=!BTA)3:E,I@4,N9#!8GD]4BDS"U$TZ0H^$+ H'KY_VZBU\ M$YH3A=I7PUR7)1M]M5)',.@M&79&1=$2]47%T+V\K':?A>\%@_4B@'6RG0#P M2]>$U#F+G;HH,NL4SBJG'U QG9 $UJ8.XQ/EPU##R6=V6UZ.% L7'D",H*[#U2BG\,:: 9HPA&JZ$R)&$X#=FO&$;(C.^9P *_H(GOOMU3CQ (R= M$+ 8Y& $_25])U&968&'V4+0MMAC^KF'N0)X"VYLW@LDUSB-2%_":F>NF,B( MQ=JTWH1*IJMW$W]\*:KYZPC,US(19 A:&@<=]16[<+!\.": M3?NR2N2?TG=WLTM%79&+HOK,[>'1ZTM[S*E3$L-@";8TM^ MRA;*=!&(J-J'P=?\2[X+44^FI"_9B7W6>2U*O@J^#A HM3D(YS [3KE$QDZ_ M+_(Q061RU=@\^\ZFH#++$#3Z L$ZO".EP3;/WKR)B39\6CP]0ZR64[@?LI5\[AH1 M)!#ZW%-HL8@\B#7LAWT$D."H7-!'@B#2OFM7KBYO-VEEBJ4PF M6M')83=\2C_N_L 1R8\/?J!C+SG \D6,7\$^!!KMRCWE6X=*&9QA1GF/#%PC M>F@.F5*V$@'SE/G/HL)C03;(YXXM%J=R8FG8!2V#9^.Z\> SXHJ8QQ\_W#( M;9;6[LFN@XENR=@76.F[PX+VCI]>+2^P@19>95'Q+&S1HFY BOH%!8<.346Q M))M$J-4$0"GDJ'*;DFZ!/FU&FGGK/)L]$B-"V>[(S#"EC#>,=>E8 9B MWHXLP"+(@%>A:"O&#J%JLR*5=_,XVRSR@=K'-$Y(ES19G!BE4!7FW=F;JXF] M.MCV-T\.K#DML$3DU\D(?"/6XUNVF7S>]]Y:!D5C^PB,4Y?#+!3/0/$X(4/0 MIZ[BAF0'68V)(NL&O*;(D)$&BH1!"U2-Z#%E !GBA0FL[+1N$2S)\\HH?L:+ M32[';@'PE3(Y;^,5F*$XA(JT,+Y Q%3D)Y5MC&R=^&6["BQ$F">OLE(75 S0 MWE<*\$Z;)*OX60^;WH$5J>)Q\# MB3L:IG!ZAA-4,B%8266F"V#)4@%##QYT^L#0C36+Z.N]T;3IMR5[!ZI6Q-PU M'L&:1-3"[MW(R QV[F(H=0.]"X[PFP@FH\\/VA?SGEU$EV,@>TVRYW*9J*KD M?&@24Y",-+!L8BD>Z(@4 4%FBR"DJ6()]D'7X,?R4'U9%'[)MU6&HJM%%LHRFB^C9:1T8@=E#X4*:%+[32&F M(>2:"LM_,EXWSWA]=?G_*Z;.>,>#.Z7RG]SVL]@,\8NUY^0&V$6PGMU?AGRZ MQ3CT#CCJ 7 JXYXLZOB0.C1Y$+>Z6>26;[C5$V^K9-*Z('*$94-N$DE4&FI3 MY(IGUJ6^Z4G!H$6+2WUQIK/LZE4_L5667KT>,BW^Z@V".BLN _^$\K-:<3-9 MO0:=E$E7C"\A!VKEXJ&*OG()3 9,MYH Q$&4PUIQAW!/OOHA\!B^9"49EA)3 M6F;-'3B/-B74R-.^1T=DU+C=- !@)SFGFY;;M/R&L(E'26Y2$ZH_X?Z&:^3 M#0CFU&:8[]S868"*E0F?G?;G<*+4'^E(Q$KRD0R!>:%%Z]@(8,^28^5 'Z*5 MR J$40<:[E22FLX\,"G0!)LY5T#:&WHQ>!-ULQXI8XTQ*!%;HMPL(EC39[>.SWUZ<= =[0/LFY0P$ MI8=!R+#RE)S -JA;!<>08-HZ)* \1THH4Y9AG.+* 58#GB$(HB% MQ4B)RRJD/NC!IJ&QX? EZ@,CC9A*1RT=8DRHT3 ')34?T@%0Y6$6T^RT/8Y$ M\-PV"1L./SS#!\9/NP;>$Z?+A@KPU4# -PA#D M77!5YAS,F% _-4AS:DQ90,K\C30E"<,AA'9$%FXN 03UQ^ERO^FU,H4M3=>P M)[V&-:YH*8Q7K>=>9K5(23G2!_W/ MZ$H*!WL7FS*=TOFPHJ)DMXL19AB8XG8P;(N@;9]C-4 M>%!91_#;&VI,A06"GARH+_LCYML:J%YVN5QV4,G$< Y@/4;Z(C#.)[9@'(F= MERJ\RCI3H5\XM@K#@>*C]I.H=J$G.&0YX!(SJAH1OL,,0&+06!=>$. $#'N ME;[HZJ[7(2[_%OM%?.'76MHR22B"\GG:C(A+G+.-Q?QK61H+9%!_55)M?L&^ MX!\U F5NWV5#>'%?#.$69,ESKWI3@60,EJH1HKZZ2_DJUR)K5>A$J$40L"P> MS2*.23)JOV>>W1^FM8!6*S)8G7/OB-.*V-9I,>5CA>B/XE:*']&_%' MVB"X@'"OR6Y&3-^D*Q =&S72(7)=^-5%Z,8U)\2YE_C51G7\<@.%FZT)I',R M:BR+W+W%]HT?Y7=V&A>[Q,# @?MCD+B_BQQA2%:0=)#XU"^O77EU\2IHN PQ MP9W[PYXE(^U4%MKZ"3]4H<,.X4Z3$J%KVJ055&<>LR)K(#(-[S4Q*0&PA&H5 M>X?UP/W+5J1^W2V;0Y#60 %]T5L@HI5U&CL[*R=KLL475]-Y)1?;8SS(9H5? MS1M1MI-RV7:N(N(^5W-*F'IKC,J(X/N%NINV3DX^CV Z8MS"'\B#3V6V\$@A M6XX'DP %,HT1\.,UA-K2'T]B]XE5, MND04"+5BDT<)E^8=33]!>+Q(*(>V(%_:Y+Q^2S8FP;U* *%CR82ZJ$M?OS), MK^"'-]U-K"WP$C"D:]@C'==Z>9192< !#.8Z$&7!Q3E;-L3D=><)("WL_FJD[)8W>4@F?5YO)5+&BU*E@] M\8I:)%,RE1GW@,=6$ *MW&73?JFM[@JER:[6N20[H-B[WN3HZ/BOKR_Q2X'8 M+$8@C(WQV)7O":FSX[%K/3:XOFT+54IO!D\(,=/C]2N'FS2X+B*^/3VNZX=; M[?)):*Y9K'9D# 7/;U@N22R?@25BT.^^;/H]1]I3Y62NJ+1HJ&9\HI+X@OR M7@<<[*U!JF)%:.AAS;DN>)E-V/$:R*#.O2D5E^H:53B7N9C8+*46(\JA56Y< MOV$BTZCH]9?*XH C ,8)NG%3*&H.C$YEIH9>$V(NQ6PVZV&1WMA.0PMO+3#< M%2.]KV@/!G 1H<2X:=PM*OR:D-H5X;M5'']M;=WRE_' M>BP)HCG=:10,1BF+WV)RG[;[Z,&CWH.]?F]G[_'>#?>U:&:Z"QN\U!Y_>Q/S M=V'TDB@H_W,>OD@'(.#?TC/)7[Y-78B'V_S-V]24R-_F_?]02P$"% ,4 M" !J1GY1#2YO GD# -# $0 @ $ :V1M;BTR,#(P M,3$S,"YX&UL4$L! A0#% @ :D9^ M4=ZHJ0NE! "BT !4 ( !]@D &MD;6XM,C R,#$Q,S!? M<')E+GAM;%!+ 0(4 Q0 ( &I&?E%"\K'&+!8 $Y/ 0 4 M " #AK+FAT;5!+ 0(4 Q0 ( &I&?E%J MTXC%31( $A< 8 " 2PE !K9&UN+3(P,C Q,3,P>&5X >.3E?,2YH=&U02P4& 4 !0!- 0 KS< end